Five actions pharmaceutical and biotechnology companies can take before the BIOSECURE Act passes.
A joint white paper with Health-ISAC and CyberCX
Biotechnology is a high-value target for strategically, economically, and commercially motivated threat actors. The Health-ISAC Threat Operations Center and CyberCX Intelligence assess three key angles to understanding biotechnology as a target.
With the BIOSECURE Act likely to pass and disrupt pharmaceutical supply chains and research and development, pharmaceutical and biotechnology companies should immediately begin preparing. Read the paper to gain some recommendations for actions companies can take today.
